Sunday 18 October 2026
Export RCKT’s income statement to Excel — free account
Rocket Pharmaceuticals, Inc.
RCKT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 275.8%, free cash flow grew 19.2% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.18
0.18
−7.63%
Follow RCKT
Rocket Pharmaceuticals, Inc. (RCKT) P/E ratio
Rocket Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 454× (April 2017) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 454×
Ten-year median
0.0×
Current reading's percentile
94
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LCTX Lineage Cell Therapeutics, Inc. compare | n/m |
| ABEO Abeona Therapeutics Inc. compare | n/m |
| PRLD Prelude Therapeutics Incorporated compare | n/m |
| VNDA Vanda Pharmaceuticals Inc. compare | n/m |
| XFOR X4 Pharmaceuticals, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| IKT Inhibikase Therapeutics, Inc. compare | n/m |
| RCKT Rocket Pharmaceuticals, Inc. | n/m |
| PALI Palisade Bio, Inc. compare | 2.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)